neffy 1 mg is the first approved needle-free epinephrine nasal spray for children aged 4 to 30 kg, addressing severe allergic reactions. ARS Pharmaceuticals announced the FDA approval of neffy 1 mg, ...
9d
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target.
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from ...
Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer of 2026 SAN DIEGO ...
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...
Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy ® (epinephrine nasal spray) 2mg for use in emergency treatment of ...
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger ...
Credit: ARS Pharmaceuticals. Each carton contains 2 blister packages each with a single-dose nasal spray product for 1 time use. It is recommended that patients be prescribed and have immediate access ...
For decades, people with severe food allergies had one emergency option: epinephrine injections, which many fear and delay—research shows just 10 to 15% of people administer them promptly during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results